Format

Send to

Choose Destination
South Asian J Cancer. 2013 Jan;2(1):44-9. doi: 10.4103/2278-330X.105896.

Challenges in launching multinational oncology clinical trials in India.

Author information

1
Breast International Group, Department of Medical Oncology, Jules Bordet Institute, Université libre de Bruxelles, Brussels, Belgium.
2
Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
3
Clinical Research, AstraZeneca Pharma India Ltd., Bangalore, Karnataka, India.
4
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA.
5
Department of Anatomie Pathologique, Cliniques Saint Luc, Université catholique de Louvain, Brussels, Belgium.
6
Indian Cooperative Oncology Network, Mumbai, Maharashtra, India.
7
INDOX Cancer Research Network, University of Oxford, Oxford, UK.
8
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.

Abstract

In the recent past, there has been an impressive growth in the number of clinical trials launched worldwide, including India. Participation in well-designed oncology clinical trials is of advantage to Indian healthcare system in general, and cancer patients in particular. However, the number of clinical trials being run in India is not commensurate with the cancer burden prevailing in the country. In this article, the authors investigate the reasons for this discrepancy, highlight critical bottlenecks, and propose ways to ameliorate the situation.

KEYWORDS:

Cancer; India; South Asia; challenges; clinical trials; delays; obstacles; oncology; regulatory; research

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center